Article thumbnail

Preparation and evaluation of ofloxacin-loaded palmitic acid solid lipid nanoparticles

By Shuyu Xie, Luyan Zhu, Zhao Dong, Yan Wang, Xiaofang Wang and WenZhong Zhou


The purpose of this study was to use solid lipid nanoparticles (SLN) to improve the pharmacological activity of ofloxacin. Ofloxacin-loaded SLN were prepared using palmitic acid as lipid matrix and poly vinyl alcohol (PVA) as emulsifier by a hot homogenization and ultrasonication method. The physicochemical characteristics of SLN were investigated by optical microscope, scanning electron microscopy, and photon correlation spectroscopy. Pharmacokinetics was studied after oral administration in mice. In vitro antibacterial activity and in vivo antibacterial efficacy of the SLN were investigated using minimal inhibitory concentrations (MIC) and a mouse protection model. The results demonstrated that the encapsulation efficiency, loading capacity, diameter, polydispersivity index, and zeta potential of the nanoparticles were 41.36% ± 1.50%, 4.40% ± 0.16%, 156.33 ± 7.51 nm, 0.26 ± 0.04, and −22.70 ± 1.40 mv, respectively. The SLN showed sustained release and enhanced antibacterial activity in vitro. Pharmacokinetic results demonstrated that SLN increased the bioavailability of ofloxacin by 2.27-fold, and extended the mean residence time of the drug from 10.50 to 43.44 hours. Single oral administrations of ofloxacin-loaded nanoparticles at 3 drug doses, 5 mg/kg, 10 mg/kg, and 20 mg/kg, all produced higher survival rates of lethal infected mice compared with native ofloxacin. These results indicate that SLN might be a promising delivery system to enhance the pharmacological activity of ofloxacin

Topics: Original Research
Publisher: Dove Medical Press
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (1991). A reappraisal of its antimicrobial activity, pharmacology and therapeutic use.
  2. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
  3. (1997). Bioadhesion of solid oral dosage forms, why and how?
  4. Bioadhesive microspheres as a controlled drug delivery system.
  5. (2011). characterization and pharmacokinetics of enrofloxacin-loaded solid lipid nanoparticles: influences of fatty acids. Colloids Surf B Biointerfaces.
  6. (1998). Clinical trial of ototopical ofloxacin for treatment of chronic suppurative otitis media. Clin Ther.
  7. Delivery of ofloxacin to the lung and alveolar macrophages via hyaluronan microspheres for the treatment of tuberculosis.
  8. Development of sustained release gastroretentive drug delivery system for ofloxacin: In vitro and in vivo evaluation.
  9. (2008). Effect of PLGA as a polymeric emulsifer on preparation of hydrophilic proteinloaded solid lipid nanoparticles. Colloids Surf B Biointerfaces.
  10. (2011). Enhancement of antibacterial activity of tilmicosin against Staphylococcus aureus by solid lipid nanoparticles in vitro and in
  11. Formulation, characterization and pharmacokinetics of praziquantel-loaded hydrogenated castor oil solid lipid nanoparticles.
  12. Hydrogenated castor oil nanoparticles as carriers for the subcutaneous administration of tilmicosin: in vitro and in vivo studies.
  13. (1997). Improved dissolution of ofloxacin via solid dispersion.
  14. (1992). In vitro and in vivo antibacterial activities of levofloxacin (L-ofloxacin), an optically active ofloxacin. Antimicrob Agents Chemother.
  15. In vitro and in vivo evaluation of ofloxacin sustained release pellets.
  16. In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against Gram-positive and Gram-negative pathogens from respiratory tract infections.
  17. (1990). In-vitro activity of ofloxacin against Mycobacterium tuberculosis and its clinical efficacy in multiply resistant pulmonary tuberculosis.
  18. Lipid – An emerging platform for oral delivery of drugs with poor bioavailability.
  19. Novel sustained release, swellable and bioadhesive gastroretentive drug delivery system for ofloxacin.
  20. Ofloxacin versus parenteral therapy for chronic osteomyelitis. Antimicrob Agents Chemother.
  21. (2000). Ofloxacin-loaded liposomes: in vitro activity and drug accumulation in bacteria. Antimicrob Agents Chemother.
  22. Oral bioavailability of cyclosporine: Solid lipid nanoparticles (SLN®) versus drug nanocrystals.
  23. Oral solid lipid nanoparticle-based antitubercular chemotherapy.
  24. (1998). Pharmacodynamics of fluoroquinolones. Clin Infect Dis.
  25. (1998). Pharmacokinetic:pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clin Infect Dis.
  26. Pharmacology of the fluoroquinolones: A perspective for the use in domestic animals.
  27. Post-antibiotic effects of ofloxacin on Escherichia coli, Klebsiella pneumoniae, Staphylococcusaureus, and Streptococcus pyogenes.
  28. Preparation and antibacterial activity evaluation of rifampicin-loaded poly lactide-co-glycolide nanoparticles.
  29. (2003). Review of the oral toxicity of polyvinyl alcohol (PVA). Food Chem Toxicol.
  30. Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art.
  31. Solid lipid nanoparticles for enhancing vinpocetine’s oral bioavailability.
  32. (2001). Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliver Rev.
  33. Susceptibility of Legionella pneumophila to ofloxacin in vitro and in experimental Legionella pneumonia in guinea pigs. Antimicrob Agents Chemother.
  34. Sustained antibacterial activity of doxycycline-loaded poly(D,L-lactide-co-glycolide) and poly(ε-caprolactone) nanoparticles.
  35. The characteristics and mechanism of simvastatin loaded lipid nanoparticles to increase oral bioavailability in rats.
  36. The comparative invitro activity of ofloxacin.
  37. The pharmacokinetics of ofloxacin and a review of its tissue penetration.
  38. (1989). Treatment of typhoid fever with ofloxacin.
  39. (2006). Two open-label, randomized, crossover studies assessing the bioequivalence of ofloxacin administered as immediateand extended-release formulations in healthy subjects. Clin Ther.